SLGL Sol-Gel Technologies Ltd.
Financings ·
Sol-Gel's first-quarter 2026 report shows $52.8 million in cash and securities at March 31 after a March offering of about $33.1 million, with revenue of $0.1 million and a net loss of $3.7 million. The company says the funds support operations into 2028.
Sol-Gel's second-quarter report shows $24.2 million in cash and securities at June 30, 2025, and net income of $11.6 million that came mostly from a one-time $16 million sale of U.S. product rights. The company's largest pipeline asset still has no results until the fourth quarter of 2026.
Nasdaq confirmed on May 22, 2025 that the bid price deficiency matter is closed. The stock closed at $1.00 or more for 13 consecutive business days.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $19.4 million | $11.5 million |
| Research and development | $22.8 million | $17.8 million |
| Net income (loss) | -$6.1 million | -$10.6 million |
| Cash from operations | $322,000 | -$13.9 million |
| Cash and equivalents | $11.0 million | $19.5 million |
| Short-term investments | $13.0 million | $4.4 million |
Our latest story on this, dated May 28, 2026: "Sol-Gel says $33.1 million March offering and $52.8 million balance fund it into 2028". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 22, 2025: "Sol-Gel Technologies regains Nasdaq minimum bid price compliance after extension". The story links the filing or release it is based on. Read the story.
Sol-Gel Technologies Ltd. trades under the ticker SLGL on NASDAQ.
Sol-Gel Technologies Ltd. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Sol-Gel Technologies Ltd. is 1684693. Its filings are on SEC EDGAR.
2,786,158 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-19.
Our directory records Sol-Gel Technologies Ltd. under Israel.
Our directory classifies Sol-Gel Technologies Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Sol-Gel Technologies Ltd. is IL0011417206.
aibio.space lists Sol-Gel Technologies Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as L3.
$19.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Sol-Gel Technologies Ltd. reported a net loss of $6.1 million for the fiscal year ended Dec 31, 2025, and generated $322,000 of cash from operations, per its annual report to the SEC.
$22.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$24.0 million in cash and short-term investments at Dec 31, 2025, per its 20-F.
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. Source
Reported a financing. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Set up an at-the-market program to sell shares over time. SEC Form F-3. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio